- Title
- Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder : an iSPOT-D report
- Creator
- Braund, Taylor; Tillman, Gabriel; Palmer, Donna; Gordon, Evian; Rush, A.; Harris, Anthony
- Date
- 2021
- Type
- Text; Journal article
- Identifier
- http://researchonline.federation.edu.au/vital/access/HandleResolver/1959.17/179527
- Identifier
- vital:15609
- Identifier
-
https://doi.org/10.1038/s41398-021-01533-1
- Identifier
- ISBN:2158-3188 (ISSN)
- Abstract
- Side effects to antidepressant medications are common and can impact the prognosis of successful treatment outcome in people with major depressive disorder (MDD). However, few studies have investigated the severity of side effects over the course of treatment and their association with treatment outcome. Here we assessed the severity of side effects and the impact of treatment type and anxiety symptoms over the course of treatment, as well as whether side effects were associated with treatment outcome. Participants were N = 1008 adults with a current diagnosis of single-episode or recurrent, nonpsychotic MDD. Participants were randomised to receive escitalopram, sertraline, or venlafaxine-extended release with equal probability and reassessed at 8 weeks regarding Hamilton Rating Scale Depression (HRSD17) and Quick Inventory of Depressive Symptomatology (QIDS-SR16) remission and response. Severity of side effects were assessed using the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale and assessed at day 4 and weeks 2, 4, 6, and 8. Frequency, intensity, and burden of side effects were greatest at week 2, then only frequency and intensity of side effects gradually decreased up to week 6. Treatment type and anxiety symptoms did not impact the severity of side effects. A greater burden—but not frequency or intensity—of side effects was associated with poorer treatment outcome and as early as 4 days post-treatment. Together, this work provides an informative mapping of the progression of side effects throughout the treatment course and their association with treatment outcome. Importantly, the burden of side effects that are present as early as 4 days post-treatment predicts poorer treatment outcome and should be monitored closely. iSPOT-D: Registry name: ClinicalTrials.gov. Registration number: NCT00693849. © 2021, The Author(s).
- Publisher
- Springer Nature
- Relation
- Translational Psychiatry Vol. 11, no. 1 (2021), p.
- Rights
- All metadata describing materials held in, or linked to, the repository is freely available under a CC0 licence
- Rights
- http://creativecommons.org/licenses/by/4.0/
- Rights
- Copyright © The Author(s) 2021
- Rights
- Open Access
- Subject
- 1103 Clinical Sciences; 1117 Public Health and Health Services; 1701 Psychology
- Full Text
- Reviewed
- Funder
- We acknowledge Brain Resource as the sponsor for the iSPOT-D study (NCT00693849).
- Hits: 2403
- Visitors: 1795
- Downloads: 112
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | SOURCE1 | Published version | 838 KB | Adobe Acrobat PDF | View Details Download |